H.R. 7877: Shane DiGiovanna Act

This bill, known as the Shane DiGiovanna Act, aims to establish a demonstration program under the Medicaid program focusing on the treatment of a rare skin condition called epidermolysis bullosa. Here’s a breakdown of what the bill entails:

Purpose

The main goal of the bill is to require the Secretary of Health and Human Services to initiate a program that will examine the implications of mandatory coverage for certain treatment options related to epidermolysis bullosa for individuals covered by Medicaid.

Duration and Implementation

The program must start no later than one year after the bill is enacted and will last for two years. It will be conducted on a nationwide basis, providing consistent access to treatment for residents across the U.S.

Treatment Items and Services Covered

The specific items and services that will be included in this coverage are:

• Over-the-counter antihistamines
• Acetaminophen
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Antiseptics
• Zinc oxide
• Antibiotic ointments
• Wound care supplies, which include:
• Wound care dressings (primary and secondary)
• Gauze
• Bandage retainers

Impact Evaluation

At the conclusion of the demonstration program, the Secretary is required to submit a report to Congress within one year. This report will include:

• An evaluation of the effect of the program on overall Medicaid expenditures for epidermolysis bullosa treatment.
• An analysis of health outcomes for individuals with epidermolysis bullosa during the program compared to their outcomes before the program started.
• Recommendations on strategies to reduce hospitalizations related to the condition.

Scope of the Program

The demonstration program aims to gather comprehensive data on how providing mandatory coverage for these treatment items can affect both the financial and health outcomes for patients suffering from epidermolysis bullosa.

Relevant Companies

None found.